Now livetag icon
2026 State of Ecommerce: Own the AI Shopper Journey.Download Reportbanner icon
Yoshindo

August 2026

Yoshindo Market Share Analysis for August 2026

総合お問い合わせページです。陽進堂グループは日々の健康と地域の発展への貢献を目指して、「なくてはならい企業」として、果敢に挑戦していきます。
Year Founded1929
Employees51 - 200
Annual Revenue$10M - $15M
yoshindo.jp
Yoshindo
Yoshindo (including company regionals)
  • yoshindo.jp
    yoshindo.jp
See more website traffic and engagement information

Yoshindo Revenue up to August 2026 is 10M - 15M

revenue generated by Yoshindo top domains

Yoshindo top domains revenue over 3 years

Revenue for Yoshindo top domains


Total visits to Yoshindo's top domains

Understand Yoshindo market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in Yoshindo's top domains

Analyze Yoshindo engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on Yoshindo's top domains

See how Yoshindo keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.



Top technologies used by Yoshindo

These are the website technologies, by industry, used by Yoshindo top domains

Mobile (1)

Meta Viewport

Meta Viewport

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from Yoshindo

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBiocon Biologics Limited partners with Yoshindo.Biocon Biologics entered into a licensing agreement with Yoshindo for the Japanese commercialization of 2 biosimilar candidates: an ustekinumab biosimilar and a denosumab biosimilar.

See all Yoshindo signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.